Cargando…

Fibroblast Growth Factor 21 Ameliorates Na(V)1.5 and Kir2.1 Channel Dysregulation in Human AC16 Cardiomyocytes

Infarcted myocardium is predisposed to cause lethal ventricular arrhythmias that remain the main cause of death in patients suffering myocardial ischemia. Liver-derived fibroblast growth factor 21 (FGF21) is an endocrine regulator, which exerts metabolic actions by favoring glucose and lipids metabo...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jiamin, Li, Yuanshi, Liu, Yining, Yu, Hang, Xu, Ning, Huang, Di, Xue, Yadong, Li, Sijia, Chen, Haixin, Liu, Jiali, Li, Qingsui, Zhao, Yiming, Zhang, Ronghao, Xue, Hongru, Sun, Yuehang, Li, Ming, Li, Pengyu, Liu, Mingbin, Zhang, Zhen, Li, Xin, Du, Weijie, Wang, Ning, Yang, Baofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493335/
https://www.ncbi.nlm.nih.gov/pubmed/34630093
http://dx.doi.org/10.3389/fphar.2021.715466
_version_ 1784579102947147776
author Li, Jiamin
Li, Yuanshi
Liu, Yining
Yu, Hang
Xu, Ning
Huang, Di
Xue, Yadong
Li, Sijia
Chen, Haixin
Liu, Jiali
Li, Qingsui
Zhao, Yiming
Zhang, Ronghao
Xue, Hongru
Sun, Yuehang
Li, Ming
Li, Pengyu
Liu, Mingbin
Zhang, Zhen
Li, Xin
Du, Weijie
Wang, Ning
Yang, Baofeng
author_facet Li, Jiamin
Li, Yuanshi
Liu, Yining
Yu, Hang
Xu, Ning
Huang, Di
Xue, Yadong
Li, Sijia
Chen, Haixin
Liu, Jiali
Li, Qingsui
Zhao, Yiming
Zhang, Ronghao
Xue, Hongru
Sun, Yuehang
Li, Ming
Li, Pengyu
Liu, Mingbin
Zhang, Zhen
Li, Xin
Du, Weijie
Wang, Ning
Yang, Baofeng
author_sort Li, Jiamin
collection PubMed
description Infarcted myocardium is predisposed to cause lethal ventricular arrhythmias that remain the main cause of death in patients suffering myocardial ischemia. Liver-derived fibroblast growth factor 21 (FGF21) is an endocrine regulator, which exerts metabolic actions by favoring glucose and lipids metabolism. Emerging evidence has shown a beneficial effect of FGF21 on cardiovascular diseases, but the role of FGF21 on ventricular arrhythmias following myocardial infarction (MI) in humans has never been addressed. This study was conducted to investigate the pharmacological effects of FGF21 on cardiomyocytes after MI in humans. Patients with arrhythmia in acute MI and healthy volunteers were enrolled in this study. Serum samples were collected from these subjects on day 1 and days 7–10 after the onset of MI for measuring FGF21 levels using ELISA. Here, we found that the serum level of FGF21 was significantly increased on day 1 after the onset of MI and it returned to normal on days 7–10, relative to the Control samples. In order to clarify the regulation of FGF21 on arrhythmia, two kinds of arrhythmia animal models were established in this study, including ischemic arrhythmia model (MI rat model) and nonischemic arrhythmia model (ouabain-induced guinea pig arrhythmia model). The results showed that the incidence and duration time of ischemic arrhythmias in rhbFGF21-treated MI rats were significantly reduced at different time point after MI compared with normal saline-treated MI rats. Moreover, the onset of the first ventricular arrhythmias was delayed and the numbers of VF and maintenance were attenuated by FGF21 compared to the rhbFGF21-untreated group in the ouabain model. Consistently, in vitro study also demonstrated that FGF21 administration was able to shorten action potential duration (APD) in hydrogen peroxide-treated AC16 cells. Mechanically, FGF21 can ameliorate the electrophysiological function of AC16 cells, which is characterized by rescuing the expression and dysfunction of cardiac sodium current (I (Na)) and inward rectifier potassium (I (k1)) in AC16 cells induced by hydrogen peroxide. Moreover, the restorative effect of FGF21 on Na(V)1.5 and Kir2.1 was eliminated when FGF receptors were inhibited. Collectively, FGF21 has the potential role of ameliorating transmembrane ion channels remodeling through the Na(V)1.5/Kir2.1 pathway by FGF receptors and thus reducing life-threatening postinfarcted arrhythmias, which provides new strategies for antiarrhythmic therapy in clinics.
format Online
Article
Text
id pubmed-8493335
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84933352021-10-07 Fibroblast Growth Factor 21 Ameliorates Na(V)1.5 and Kir2.1 Channel Dysregulation in Human AC16 Cardiomyocytes Li, Jiamin Li, Yuanshi Liu, Yining Yu, Hang Xu, Ning Huang, Di Xue, Yadong Li, Sijia Chen, Haixin Liu, Jiali Li, Qingsui Zhao, Yiming Zhang, Ronghao Xue, Hongru Sun, Yuehang Li, Ming Li, Pengyu Liu, Mingbin Zhang, Zhen Li, Xin Du, Weijie Wang, Ning Yang, Baofeng Front Pharmacol Pharmacology Infarcted myocardium is predisposed to cause lethal ventricular arrhythmias that remain the main cause of death in patients suffering myocardial ischemia. Liver-derived fibroblast growth factor 21 (FGF21) is an endocrine regulator, which exerts metabolic actions by favoring glucose and lipids metabolism. Emerging evidence has shown a beneficial effect of FGF21 on cardiovascular diseases, but the role of FGF21 on ventricular arrhythmias following myocardial infarction (MI) in humans has never been addressed. This study was conducted to investigate the pharmacological effects of FGF21 on cardiomyocytes after MI in humans. Patients with arrhythmia in acute MI and healthy volunteers were enrolled in this study. Serum samples were collected from these subjects on day 1 and days 7–10 after the onset of MI for measuring FGF21 levels using ELISA. Here, we found that the serum level of FGF21 was significantly increased on day 1 after the onset of MI and it returned to normal on days 7–10, relative to the Control samples. In order to clarify the regulation of FGF21 on arrhythmia, two kinds of arrhythmia animal models were established in this study, including ischemic arrhythmia model (MI rat model) and nonischemic arrhythmia model (ouabain-induced guinea pig arrhythmia model). The results showed that the incidence and duration time of ischemic arrhythmias in rhbFGF21-treated MI rats were significantly reduced at different time point after MI compared with normal saline-treated MI rats. Moreover, the onset of the first ventricular arrhythmias was delayed and the numbers of VF and maintenance were attenuated by FGF21 compared to the rhbFGF21-untreated group in the ouabain model. Consistently, in vitro study also demonstrated that FGF21 administration was able to shorten action potential duration (APD) in hydrogen peroxide-treated AC16 cells. Mechanically, FGF21 can ameliorate the electrophysiological function of AC16 cells, which is characterized by rescuing the expression and dysfunction of cardiac sodium current (I (Na)) and inward rectifier potassium (I (k1)) in AC16 cells induced by hydrogen peroxide. Moreover, the restorative effect of FGF21 on Na(V)1.5 and Kir2.1 was eliminated when FGF receptors were inhibited. Collectively, FGF21 has the potential role of ameliorating transmembrane ion channels remodeling through the Na(V)1.5/Kir2.1 pathway by FGF receptors and thus reducing life-threatening postinfarcted arrhythmias, which provides new strategies for antiarrhythmic therapy in clinics. Frontiers Media S.A. 2021-09-22 /pmc/articles/PMC8493335/ /pubmed/34630093 http://dx.doi.org/10.3389/fphar.2021.715466 Text en Copyright © 2021 Li, Li, Liu, Yu, Xu, Huang, Xue, Li, Chen, Liu, Li, Zhao, Zhang, Xue, Sun, Li, Li, Liu, Zhang, Li, Du, Wang and Yang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Li, Jiamin
Li, Yuanshi
Liu, Yining
Yu, Hang
Xu, Ning
Huang, Di
Xue, Yadong
Li, Sijia
Chen, Haixin
Liu, Jiali
Li, Qingsui
Zhao, Yiming
Zhang, Ronghao
Xue, Hongru
Sun, Yuehang
Li, Ming
Li, Pengyu
Liu, Mingbin
Zhang, Zhen
Li, Xin
Du, Weijie
Wang, Ning
Yang, Baofeng
Fibroblast Growth Factor 21 Ameliorates Na(V)1.5 and Kir2.1 Channel Dysregulation in Human AC16 Cardiomyocytes
title Fibroblast Growth Factor 21 Ameliorates Na(V)1.5 and Kir2.1 Channel Dysregulation in Human AC16 Cardiomyocytes
title_full Fibroblast Growth Factor 21 Ameliorates Na(V)1.5 and Kir2.1 Channel Dysregulation in Human AC16 Cardiomyocytes
title_fullStr Fibroblast Growth Factor 21 Ameliorates Na(V)1.5 and Kir2.1 Channel Dysregulation in Human AC16 Cardiomyocytes
title_full_unstemmed Fibroblast Growth Factor 21 Ameliorates Na(V)1.5 and Kir2.1 Channel Dysregulation in Human AC16 Cardiomyocytes
title_short Fibroblast Growth Factor 21 Ameliorates Na(V)1.5 and Kir2.1 Channel Dysregulation in Human AC16 Cardiomyocytes
title_sort fibroblast growth factor 21 ameliorates na(v)1.5 and kir2.1 channel dysregulation in human ac16 cardiomyocytes
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493335/
https://www.ncbi.nlm.nih.gov/pubmed/34630093
http://dx.doi.org/10.3389/fphar.2021.715466
work_keys_str_mv AT lijiamin fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes
AT liyuanshi fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes
AT liuyining fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes
AT yuhang fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes
AT xuning fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes
AT huangdi fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes
AT xueyadong fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes
AT lisijia fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes
AT chenhaixin fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes
AT liujiali fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes
AT liqingsui fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes
AT zhaoyiming fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes
AT zhangronghao fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes
AT xuehongru fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes
AT sunyuehang fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes
AT liming fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes
AT lipengyu fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes
AT liumingbin fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes
AT zhangzhen fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes
AT lixin fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes
AT duweijie fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes
AT wangning fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes
AT yangbaofeng fibroblastgrowthfactor21amelioratesnav15andkir21channeldysregulationinhumanac16cardiomyocytes